RedHill Biopharma Ltd., an Israeli biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. The company's pipeline of therapeutic candidates include RHB-105 intended for the eradication of Helicobacter pylori infection that is under Phase III study; RHB-104 for the treatment of Crohn's disease, which is under Phase III study; BEKINDA for the prevention of chemotherapy and radiotherapy induced nausea and vomiting, and gastroenteritis and gastritis that is under phase III study; and RHB-106 intended for the preparation and cleansing of the gastrointestinal tract. Its pipeline of therapeutic candidates also comprise MESUPRON, a urokinase-type plasminogen activator inhibitor targeting gastrointestinal and other solid tumor cancers that has completed Phase II-stage; RP101, a Hsp27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers; RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines; and RHB-101 for the treatment of hypertension, heart failure, and left ventricular dysfunction. The company was founded in 2009 and is based in Tel Aviv, Israel. RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap of around $150 Million and $60+ Million in cash makes this Biotech one of the most attractive in the Sector . This low float Stock is a gift below $10 with good News we could see $50 easily by end of next year . Market Cap :$148 Million Cash: $62 Million Price: 9.70 Shares out 15 Million (50% of Shares held by Insiders alone) New Presentation http://files.shareholder.com/downlo..._Biopharma_Corporate_Presentation_151216_.pdf Upcoming Milestones Q4 2016: Commercial asset: •Potential acquisition of certain commercial rights to GI asset currently on the market in the U.S. 1H 2017 : RIZAPORT®(RHB-103): •Re-submission of U.S. NDA RHB-104: •Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and interim efficacy analysis, with evaluation of option of early stop for success for overwhelming efficacy -Q2/2017 <<<<<<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $5+ BILLION BEKINDA®(RHB-102): •Top-line Phase III results (gastroenteritis) -mid-2017 <<<< MARKET SIZE $650+ MILLION •Top-line Phase II results (IBS-D) -mid-2017 RHB-105 (H. pylori): First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated H1/2017 <<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $4+ Billion
YES Its the ongoing Share Offering which created this great opportunity . The Stock is way oversold with a RSI of 21 should rebound to $11+ quickly .Management alone owns almost 50% of the Company they have great board members which coming from Teva Pharma (TEVA) and Eagle Pharma(EGRX) i think this one is a no brainer at current levels .GL and happy holidays ! http://stockcharts.com/c-sc/sc?s=rdhl&p=D&yr=0&mn=9&dy=0&i=p93834726544&r=3658
Looks like the Rebound is ongoing ...here is one of the reasons why i bought this Goldmine .Ok guys have a nice Weekend . Dan Suesskind , Director Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind was a member of Teva’s board of directors until recently. RedHill Biopharma's RHB-104: A Potential Game Changer for Crohn's Disease? http://www.bionapcfa.com/2015/10/redhill-biopharmas-rhb-104-potential.html The opportunity for RedHill Biopharma with RHB-104 looks significant. If the Phase 3 trial is successful, I think the market will start to view RHB-104 as having peak sales in the $500-750 million range for the U.S., with potential expansion to over one billion on a global basis.
Great Analysis by J.Napodano he says stock should valued at $500 M ( currently around $150 M includes new shares offering) RedHill Expects An Eventful Next Few Months http://www.talkmarkets.com/content/...pects-an-eventful-next-few-months?post=112761 That being said, I believe RedHill BioPharma is worth approximately $500 million in value today. I see the most valuable asset as RHB-104 for Crohn's disease, followed by RHB-105 for H. pylori infection. Other important assets include Bekinda for gastroenteritis and IBS-D, RHB-104 for MS, and Yeliva and Mesupron in mid-stage development for various oncology indications. The company held $40.5 million in cash as of September 30, 2016, of which I'm including only $25 million into my sum-of-parts analysis. The company has no debt.
One of the largest and oldest Insurance company in Israel ups stake in Redhill http://ih.advfn.com/p.php?pid=nmona&article=73508837
Great News ..and stock is still brutally underpriced .GL RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal® http://finance.yahoo.com/news/redhill-biopharma-announces-exclusive-u-120202902.html Dror Ben-Asher, Chief Executive Officer of RedHill, said: "We are pleased to partner with Concordia for the U.S. promotion of Donnatal®, a trusted brand among physicians for symptoms of IBS and acute enterocolitis5. With a core U.S. commercial team in place, we plan to initiate promotional activities in the U.S. in the coming months with a specialty gastrointestinal sales force. RedHill`s strategic transition into a revenue-generating, gastrointestinal-focused, specialty pharmaceutical company with commercial presence in the U.S., is planned to support potential future commercialization of our Phase III-stage potential blockbusters BEKINDA® for gastroenteritis and other GI indications, RHB-105 for H. pylori infection and RHB-104 for Crohn`s disease, if approved by FDA."
